

**IN THE CLAIMS**

1. (currently amended) A kit combination useful for sequential administration in anticancer therapy, comprising:

- a. oxaliplatin,
- b. injectable calcium, and
- c. injectable magnesium for administration both before and after oxaliplatin treatment, and
- d. calcium in oral administration form for administration following oxaliplatin treatment;

wherein the injectable calcium and calcium in oral administration form are separate compositions.

2. (cancelled)

3. (cancelled)

4. (currently amended) The kit combination of claim 1, wherein both the injectable calcium and calcium in oral administration form are separately is present as a gluconate, bromogalactogluconate, gluconolactate or carbonate salt, and the injectable magnesium is present as a sulfate or pidolate salt.

5. (currently amended) The kit combination of claim 4, ~~wherein part of the calcium is in injectable form and the other part is in oral form, and~~ wherein the cation of said injectable calcium salt is present in a concentration between 8 and 20 mg/ml, and wherein the cation of said injectable magnesium salt is present in a concentration between 10 and 20 mg/ml, the concentrations being expressed as calcium or magnesium ions, respectively.

6. (currently amended) A method of inhibiting or treating neurotoxicity caused by the administration of oxaliplatin, comprising: (a) administering by injection to a patient both prior to and after administration of oxaliplatin of at least 1 g calcium and at least 1 g of magnesium effective to inhibit or treat the neurotoxicity, and (b) administering calcium by the oral route as a gluconate, chloride, bromogalactogluconate,

gluconolactate or carbonate salt following the treatment with oxaliplatin.

7. (cancelled)

8. (cancelled)

9. (cancelled)

10. (cancelled)

11. (currently amended) The method of claim 6, wherein said calcium and magnesium ~~are administered by injection to the patient are administered in injectable form separately.~~

12. (currently amended) The kit ~~combination~~ of claim 5, wherein the concentration of said injectable magnesium salt is 15 mg/ml.

13. (currently amended) The method of claim 6, wherein the calcium administered by the oral route is ~~additionally administered at a dose of at least 1 g/day by the oral route following the treatment with oxaliplatin.~~

14. (currently amended) The method of claim 13, wherein the calcium administered by the oral route following treatment with oxaliplatin is administered for 8 days after treatment with oxaliplatin.